Jasper Therapeutics posts updated corporate presentation highlighting c-Kit approach and briquilimab

Jasper Therapeutics, Inc.

Filed an updated corporate presentation (Exhibit 99.1) dated January 2023 under Item 7.01.
Presentation titled 'Harnessing the Power of Jasper’s Differentiated c-Kit Therapeutic Approach'.
Briquilimab described as an investigative drug not approved for any indication.
No specific financial or clinical updates provided in the furnished exhibit.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.